Literature DB >> 11313828

MHC class II presentation of endogenously expressed antigens by transfected dendritic cells.

S S Diebold1, M Cotten, N Koch, M Zenke.   

Abstract

Dendritic cells (DC) present immunogenic epitopes of antigens in the context of MHC class I and class II molecules in association with costimulatory molecules, and efficiently activate both cytotoxic T cells and T helper cells. Gene modified DC expressing antigen encoding cDNA represent a particularly attractive approach for the immunotherapy of disease. We previously described a gene delivery system for DC based on receptor-mediated endocytosis of ligand/polyethylenimine (PEI) DNA transfer complexes that target cell surface receptors which are abundantly expressed on DC. Employing this gene delivery system, DC were generated that express chicken ovalbumin (OVA) cDNA as a model antigen and introduce antigen into the MHC class I presentation pathway. We demonstrate here that modification of OVA cDNA as transferrin receptor (TfR) or invariant chain (Ii) fusions effectively generate MHC class II specific immune responses in addition to MHC class I responses. TfR-OVA contains the membrane anchoring region of transferrin receptor and represents a membrane-bound form of OVA for access to the MHC class II compartment. Ii-OVA fusions directly target the MHC class II processing pathway. Thus, modification of antigen encoding cDNA represents a convenient and effective means to direct antigens to MHC class II presentation and thus to generate T cell help.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313828     DOI: 10.1038/sj.gt.3301433

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  24 in total

Review 1.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

2.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.

Authors:  Godwin Nchinda; Janelle Kuroiwa; Margarita Oks; Christine Trumpfheller; Chae Gyu Park; Yaoxing Huang; Drew Hannaman; Sarah J Schlesinger; Olga Mizenina; Michel C Nussenzweig; Klaus Uberla; Ralph M Steinman
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.

Authors:  Emeline Ragonnaud; Peter Holst
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 4.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

5.  Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses against Plasmodium falciparum Antigens after Adenoviral Vaccination.

Authors:  Cyrielle Fougeroux; Louise Turner; Anders Miki Bojesen; Thomas Lavstsen; Peter Johannes Holst
Journal:  J Immunol       Date:  2019-03-04       Impact factor: 5.422

6.  Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.

Authors:  Frank Thiele; Sha Tao; Yi Zhang; Andreas Muschaweckh; Tina Zollmann; Ulrike Protzer; Rubert Abele; Ingo Drexler
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

7.  Pseudotyping lentiviral vectors with lymphocytic choriomeningitis virus glycoproteins for transduction of dendritic cells and in vivo immunization.

Authors:  Chupei Zhang; Biliang Hu; Liang Xiao; Yarong Liu; Pin Wang
Journal:  Hum Gene Ther Methods       Date:  2014-12       Impact factor: 2.396

8.  Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses.

Authors:  Helen M Rowe; Luciene Lopes; Najmeeyah Brown; Sofia Efklidou; Timothy Smallie; Sarah Karrar; Paul M Kaye; Mary K Collins
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

9.  Improved biolistic transfection of hair cells.

Authors:  Hongyu Zhao; Matthew R Avenarius; Peter G Gillespie
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

10.  Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity.

Authors:  Jing-Yue Yang; Xiao Li; Li Gao; Zeng-Hui Teng; Wen-Chao Liu
Journal:  Exp Ther Med       Date:  2012-07-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.